Three cases of Philadelphia (Ph) chromosome-negative, bcr-negative chronic myeloid leukaemia (CML) have been investigated for oncogene expression by Northern blot and cytoplasmic RNA dot blot hybridization. Considerably high levels of expression of c-abl and c-myb were observed in all cases. In the Ph-negative cells the normal 6.0 and 7.0 kb c-abl and 3.8 kb c-myb transcripts were found. No amplification of c-abl or c-myb oncogenes was detected in the DNAs of Ph-negative CML cells. Data suggest that co-operation between the overexpressed c-abl and c-myb oncogenes is causally related to Ph-negative bcr-negative CML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0145-2126(94)90021-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
c-myb is involved in CML progression and is a therapeutic target in the zebrafish CML model.
Animal Model Exp Med
April 2024
Division of Cell, Developmental and Integrative Biology, School of Medicine, South China University of Technology, Guangzhou, China.
Background: Despite the success of tyrosine kinase inhibitors in chronic myeloid leukemia (CML) therapy, CML still faces the challenges of drug resistance and progression to blast crisis. Twenty-five percent of patients have imatinib resistance and treatment difficulties due to heterogeneity after progression, but little is known about the mechanism. A key transcription factor in hematopoiesis, MYB, has been reported to increase abnormally in several types of aggressive blood disorders including CML.
View Article and Find Full Text PDFTargeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.
Genes (Basel)
August 2021
Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Ph+ ALL is a poor-prognosis leukemia subtype driven by the oncogene, either the p190- or the p210-BCR/ABL isoform in a 70:30 ratio. Tyrosine Kinase inhibitors (TKIs) are the drugs of choice in the therapy of Ph+ ALL. In combination with standard chemotherapy, TKIs have markedly improved the outcome of Ph+ ALL, in particular if this treatment is followed by bone marrow transplantation.
View Article and Find Full Text PDFBCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Haematologica
December 2018
Institute of Hematology and Blood Transfusion, Prague, Czech Republic
The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been proposed that it deregulates signaling networks involving both transcription factors and non-coding microRNAs that result in chronic myeloid leukemia (CML). Previously, microRNA expression profiling showed deregulated expression of miR-150 and miR-155 in CML. In this study, we placed these findings into the broader context of the MYC/miR-150/MYB/miR-155/PU.
View Article and Find Full Text PDFMYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.
J Pathol
July 2017
Equipe thérapie génique, INSERM U 1035 Biothérapie des maladies génétiques et cancers, University of Bordeaux, Bordeaux, France.
Acute basophilic leukaemia (ABL) is a rare subtype of acute myeloblastic leukaemia. We previously described a recurrent t(X;6)(p11;q23) translocation generating an MYB-GATA1 fusion gene in male infants with ABL. To better understand its role, the chimeric MYB-GATA1 transcription factor was expressed in CD34-positive haematopoietic progenitors, which were transplanted into immunodeficient mice.
View Article and Find Full Text PDFAnalysis of microRNA and gene networks in human chronic myelogenous leukemia.
Mol Med Rep
January 2016
College of Science, Dalian Ocean University, Dalian, Liaoning 116023, P.R. China.
Molecular biologists have identified a number of genes and microRNAs (miRs) associated with chronic myelogenous leukemia (CML). However, their underlying mechanisms in CML remain unclear. In the present study, three regulatory networks of genes and miRs were constructed to elucidate the underlying mechanisms of CML.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!